医药中间体市场－全球产业规模、份额、趋势、机会、预测：按产品、应用、地区和竞争对手划分，2021-2031年

全球医药中间体市场预计将从 2025 年的 436.4 亿美元成长到 2031 年的 605.5 亿美元，复合年增长率为 5.61%。

医药中间体是合成活性药物成分 (API) 的关键结构单元，是重要的化合物。全球医药中间体市场的发展主要受慢性病日益普遍、治疗方法不断创新以及学名药生产规模扩大的推动。此外，对合约研发生产机构 (CDMO) 的依赖性不断增强也为该行业提供了支持。推动这一市场扩张的主要因素是药物研发领域的大量资金投入。根据欧洲製药工业协会联合会 (EFPIA) 的报告，到 2024 年，欧洲以研发为导向的製药业在研发方面的投资金额约为 550 亿欧元。如此庞大的投资凸显了市场对新药研发所需复杂化学前驱物的强劲需求。

儘管成长前景强劲，但市场仍面临与严格的环境法规和合法规相关的重大障碍。製造商必须遵守有关化学品安全和污染防治的严格国际标准，这通常需要耗资巨大的基础设施升级和製程调整。这种复杂的法规环境，加上原物料价格的波动，造成了营运压力，可能会限制产能并阻碍全球医药中间体市场的进一步扩张。

市场驱动因素

全球慢性病和老龄化相关疾病发生率的上升是推动医药中间体产业发展的主要动力，显着增加了治疗药物生产所需的化学前体数量。随着癌症等复杂疾病在全球范围内负担加重，製造商面临着供应合成靶向药物活性成分（API）所需复杂中间体的巨大压力。世界卫生组织（WHO）2024年2月发布的题为《全球癌症负担》的新闻稿指出，2022年全球新增癌症病例预计将达到2,000万例，凸显了治疗药物生产需求的重要性。这一趋势在主要市场尤为显着，美国癌症协会发布的《2024年癌症事实与数据》预测，美国新增癌症病例数将首次超过200万例。这些人口结构的变化正直接促使该产业扩大癌症相关中间体的产能，以便患者能够获得挽救生命的治疗。

全球对经济实惠的学名药的需求不断增长，进一步推动了市场扩张，因为这需要大规模的化学合成。随着医疗保健系统寻求控制不断上涨的成本，对专利到期疗法的依赖性日益增强，从而带动了仿製药大规模生产所需基础成分的消耗。这种转变迫使中间供应商优化合成路线并加强供应链，以满足学名药产业庞大的需求。根据美国可及药品协会 (Accessible Medicines Association) 于 2024 年 9 月发布的《2024 年美国非专利和生物类似药节省报告》，学名药和生物类似药占美国所有处方笺的 90%。如此高的市场渗透率要求化学品製造商实施高效的大规模生产工艺，以满足学名药行业对原材料的巨大需求。

市场挑战

严格的环境法规和合法规对全球医药中间体市场的扩张构成重大阻碍。各国政府强制执行有关化学品安全、废弃物管理和污染防治的严格通讯协定，迫使製造商将大量资金投入无法产生收益的基础建设。这些合规要求推高了营运成本，延长了生产週期，并直接降低了企业应对全球需求波动所需的灵活性。因此，企业往往面临利润率下降，难以再投资于设施现代化和产能扩张。

这些监管压力对工业产出和竞争力产生了重大影响。据欧洲化学工业理事会（Cefic）称，作为医药中间体主要来源的整个欧洲化学行业的运转率在2024年将停滞在75%左右，远低于历史平均水平，这主要是由于高昂的监管成本和运营成本的双重负担。如此低的运转率利用率凸显了合规义务如何限制生产效率。最终，这些营运限制会造成供应瓶颈，并透过推高关键医药前驱物的成本结构来阻碍整体市场成长潜力。

市场趋势

随着製药公司将韧性置于低成本采购之上，以美国、欧洲和「中国+1」策略为驱动的供应链多元化策略转型正在从根本上改变市场结构。面对地缘政治风险和供应脆弱性，主要企业投入大量资金加强国内生产基地，以减少对单一海外供应来源的依赖。为了支持这种透过区域多元化实现安全保障的趋势，DCAT价值链洞察在其2025年11月发布的「产业热点新闻」更新报告中指出，再生元製药计画投资20亿美元用于其在美国的製药生产业务，以增强国内产能。

同时，胜肽、寡核苷酸和抗体药物复合体(ADC) 等特种中间体的扩张正在推动产业内的技术进步。与传统的小分子药物不同，这些复杂的药物需要高度精密的合成工艺，例如固相肽合成，并正在形成其自身的高价值市场细分领域。随着对 GLP-1促效剂和标靶癌症疗法的需求激增，合约研发生产机构 (CDMO) 不得不积极扩大其专业生产能力，以应对这些复杂的化学过程。例如，DCAT Value Chain Insights 在 2025 年 4 月报道称，Corden Pharma 已决定进行超过 10 亿欧元的战略投资，以提高其胜肽的生产能力。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球医药中间体市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类型（化学中间体、医药原料中间体、客製化中间体、其他）
  • 依用途分类（镇痛药、抗发炎药、循环系统药物、抗糖尿病药物、抗癌药物等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美医药中间体市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲医药中间体市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区医药中间体市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲医药中间体市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲医药中间体市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章 全球医药中间体市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Aceto Corporation
• BASF SE
• Chiracon GmbH
• Yin-sheng Bio-tech Co. Ltd.
• Dishman Pharmaceuticals & Chemicals Ltd
• Green Vision Life Sciences Pvt Ltd
• Midas Pharma GmbH
• Sanofi SA
• Vertellus Holdings LLC.
• Lonza Group AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Pharmaceutical Intermediates Market is projected to expand from USD 43.64 Billion in 2025 to USD 60.55 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 5.61%. Pharmaceutical intermediates are specialized chemical compounds that function as the essential building blocks for synthesizing active pharmaceutical ingredients (APIs). This global market is driven by the increasing prevalence of chronic diseases, which demands continuous therapeutic innovation, alongside the growing production of generic medicines. Additionally, the industry is supported by a rising reliance on Contract Development and Manufacturing Organizations (CDMOs). A key factor fueling this expansion is the significant capital dedicated to drug discovery; the European Federation of Pharmaceutical Industries and Associations reported that the research-based pharmaceutical sector invested roughly €55,000 million in R&D across Europe in 2024. This substantial investment highlights the strong demand for the complex chemical precursors necessary for developing new medications.

Despite these favorable growth prospects, the market faces a major hurdle regarding strict environmental and regulatory compliance. Manufacturers are required to adhere to rigorous international standards regarding chemical safety and pollution control, often mandating expensive infrastructure upgrades and process adjustments. This complicated regulatory environment, combined with the potential for raw material price volatility, creates operational pressures that may limit production capacities and hinder the broader expansion of the global pharmaceutical intermediates market.

Market Driver

The rising global incidence of chronic and age-related disorders serves as a primary driver for the pharmaceutical intermediates sector, significantly increasing the volume of chemical precursors needed for therapy production. As the burden of complex diseases like cancer grows worldwide, manufacturers face intense pressure to supply advanced intermediate chemicals required for synthesizing targeted Active Pharmaceutical Ingredients (APIs). According to the World Health Organization's 'Global Cancer Burden' press release in February 2024, there were an estimated 20 million new cancer cases globally in 2022, emphasizing the critical scale of demand for therapeutic manufacturing. This trend is particularly evident in major markets; the American Cancer Society's 'Cancer Facts & Figures 2024' projected that new cancer cases in the United States would exceed 2 million for the first time. These demographic shifts directly compel the industry to boost production capacities for oncology-related intermediates to ensure patient access to life-saving treatments.

The accelerating global demand for cost-effective generic medications further supports market expansion by requiring high-volume chemical synthesis. As healthcare systems seek to control rising costs, the reliance on off-patent therapeutics has increased, driving the consumption of the fundamental building blocks necessary for their mass production. This shift forces intermediate suppliers to optimize synthetic routes and strengthen supply chains to meet the bulk volume needs of the generics sector. According to the Association for Accessible Medicines' '2024 U.S. Generic & Biosimilar Medicines Savings Report' from September 2024, generic and biosimilar medicines comprised 90% of all prescriptions filled in the United States. This significant market penetration obliges chemical manufacturers to adopt efficient, large-scale processes to satisfy the substantial material requirements of the generic drug industry.

Market Challenge

Strict environmental and regulatory compliance constitutes a formidable obstacle to the expansion of the Global Pharmaceutical Intermediates Market. As governments enforce rigorous protocols regarding chemical safety, waste management, and pollution control, manufacturers are forced to allocate significant capital toward non-revenue-generating infrastructure upgrades. These compliance mandates raise operational costs and extend production timelines, directly reducing the agility needed to respond to fluctuating global demand. Consequently, companies often experience diminished profit margins, which limits their ability to reinvest in facility modernization or capacity expansion.

This regulatory pressure has a tangible impact on industrial output and competitiveness. According to the European Chemical Industry Council (Cefic), capacity utilization across the European chemical sector-a vital source for pharmaceutical intermediates-stagnated at approximately 75% in 2024, a figure significantly below the historical average due to the compounding burdens of high regulatory and operational costs. Such underutilization underscores how compliance obligations can restrict manufacturing throughput. Ultimately, these operational constraints impede the market's overall growth potential by causing supply bottlenecks and driving up the cost structure of essential pharmaceutical precursors.

Market Trends

The strategic pivot toward Western and "China Plus One" supply chain diversification is fundamentally reshaping the market as pharmaceutical companies value resilience over low-cost sourcing. Facing geopolitical risks and supply vulnerabilities, major industry players are actively reshoring production to the United States and Europe or diversifying into alternative Asian hubs to secure their intermediate supply chains. This structural realignment drives significant capital allocation into domestic manufacturing resilience, reducing dependence on single-source foreign entities. Validating this trend toward localized security, DCAT Value Chain Insights reported in its November 2025 'Top Industry News' update that Regeneron plans to invest $2 billion in United States drug manufacturing operations to bolster its domestic production capabilities.

Simultaneously, the expansion of specialized intermediates for peptides, oligonucleotides, and Antibody-Drug Conjugates is driving a technological evolution within the sector. Unlike traditional small molecules, these complex modalities require highly sophisticated synthetic steps, such as solid-phase peptide synthesis, creating a distinct, high-value market segment. The surging demand for GLP-1 agonists and targeted oncology therapies compels CDMOs to aggressively expand specialized capacity to handle these intricate chemical processes. Illustrating this investment in high-value infrastructure, DCAT Value Chain Insights noted in April 2025 that CordenPharma committed to a strategic investment exceeding €1 billion to increase its peptide manufacturing capacity.

Key Market Players

• Aceto Corporation
• BASF SE
• Chiracon GmbH
• Yin-sheng Bio-tech Co. Ltd.
• Dishman Pharmaceuticals & Chemicals Ltd
• Green Vision Life Sciences Pvt Ltd
• Midas Pharma GmbH
• Sanofi SA
• Vertellus Holdings LLC.
• Lonza Group AG

Report Scope

In this report, the Global Pharmaceutical Intermediates Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Intermediates Market, By Product

• Chemical Intermediates
• Bulk Drug Intermediates
• Custom Intermediates
• Others

Pharmaceutical Intermediates Market, By Application

• Analgesics
• Anti-inflammatory Drug
• Cardiovascular Drugs
• Anti-Diabetic Drugs
• Anti-Cancer Drugs
• Others

Pharmaceutical Intermediates Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Intermediates Market.

Available Customizations:

Global Pharmaceutical Intermediates Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical Intermediates Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Chemical Intermediates, Bulk Drug Intermediates, Custom Intermediates, Others)
  • 5.2.2. By Application (Analgesics, Anti-inflammatory Drug, Cardiovascular Drugs, Anti-Diabetic Drugs, Anti-Cancer Drugs, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Pharmaceutical Intermediates Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pharmaceutical Intermediates Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Pharmaceutical Intermediates Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Pharmaceutical Intermediates Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application

7. Europe Pharmaceutical Intermediates Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pharmaceutical Intermediates Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
  • 7.3.2. France Pharmaceutical Intermediates Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Pharmaceutical Intermediates Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Pharmaceutical Intermediates Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Pharmaceutical Intermediates Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application

8. Asia Pacific Pharmaceutical Intermediates Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pharmaceutical Intermediates Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
  • 8.3.2. India Pharmaceutical Intermediates Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Pharmaceutical Intermediates Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Pharmaceutical Intermediates Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Pharmaceutical Intermediates Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application

9. Middle East & Africa Pharmaceutical Intermediates Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pharmaceutical Intermediates Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Pharmaceutical Intermediates Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Pharmaceutical Intermediates Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application

10. South America Pharmaceutical Intermediates Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pharmaceutical Intermediates Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Pharmaceutical Intermediates Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Pharmaceutical Intermediates Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pharmaceutical Intermediates Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Aceto Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. BASF SE
• 15.3. Chiracon GmbH
• 15.4. Yin-sheng Bio-tech Co. Ltd.
• 15.5. Dishman Pharmaceuticals & Chemicals Ltd
• 15.6. Green Vision Life Sciences Pvt Ltd
• 15.7. Midas Pharma GmbH
• 15.8. Sanofi SA
• 15.9. Vertellus Holdings LLC.
• 15.10. Lonza Group AG

16. Strategic Recommendations

17. About Us & Disclaimer